Agilent Q3 Revenues Slide 4 Percent; Beats Analyst Estimates on Top, Bottom Lines | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Wednesday that revenues for its fiscal third quarter shrank 4 percent year over year, although the Diagnostics and Genomics segment saw revenues grow 54 percent.

The company brought in a total of $1.65 billion for the three months ended July 31, down from $1.72 billion a year ago, but narrowly edging out the average Wall Street estimate of $1.64 billion.

Orders were down 4 percent year over year to $1.60 billion from $1.66 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.